Orgenesis completes acquisition of Koligo Therapeutics and announces additional acquisition of Icellator(R) Technology from Tissue Genesis in related transaction
Icellator(R) commercially available for lipotransfer in first two countries with more approvals expected
Germantown, MD, US October 19th, 2020 Orgenesis Inc. (NASDAQ: ORGS)(Orgenesis or the Company), a global biotech company working to unlock the full potential of celland gene therapies, today announced completion of thepreviously announcedacquisition ofKoligo Therapeutics, Inc.(Koligo), a regenerative medicine company. Additionally, the Company announced that it has acquired substantially all of the assets ofTissue Genesis, LLC(Tissue Genesis), adding to a growing list of POCare technology resources.
The acquisition of Tissue Genesis was initially undertaken via Koligo Therapeutics, Inc., and became part of the Koligo acquisition transaction. Orgenesis will now own the entire inventory of Tissue GenesisIcellator(R) devices, related kits and reagents, a broad patent portfolio to protect the technology, registered trademarks, clinical data, and existing business relationships for commercial and development stage use of the Icellator technology.
The Icellator device is a point-of-care cell isolation technology that rapidly recovers high yields of stromal and vascular cells (SVF) from adipose tissue (fat) to be used therapeutically. Adipose tissue is recognized as a superior source for adult stem cells found abundantly in the micro-vasculature and stroma of human fat. Further details include:
With the Koligo acquisition closed, we believe that we are making rapid progress on a number of fronts, said Vered Caplan, CEO of Orgenesis. Specifically, we plan to leverage the therapies and technologies from Koligo and Tissue Genesis across our POCare Platform. One of our first goals is to accelerate the commercial scaleup of KYSLECEL throughout the United States and, subject to regulatory and logistical considerations, in international markets as well. Subject to FDA review and clearance of our IND application, we also look forward to commencing patient recruitment for a phase 2 randomized clinical trial of KT-PC-301, an autologous clinical development stage cell therapy candidate for COVID-19-related Acute Respiratory Distress Syndrome, or ARDS. We plan to use the Icellator device to support scalable, cost-effective production of KT-PC-301. Additionally, Koligos development stage 3D-V bioprinting technology for the vascularization of autologous cells to create biodegradable and shelf-stable three-dimensional cell and tissue implants will be explored for diabetes and pancreatitis applications, with longer term applications for neural, liver, and other cell/tissue transplants also potentially explored.
The Icellator system is highly complementary to our POCare technology systems, as well as Koligos 3D-V bioprinting technology. Technologies such as these support our mission of improving the efficacy and lowering the costs of cell and gene therapies by delivering autologous cell therapies at the point of care through our global network of hospitals and healthcare institutions, concluded Caplan.
Under the terms of the Koligo merger agreement, Orgenesis acquired all of the outstanding stock of Koligo from its shareholders for approximately USD 14.5 million in shares of Orgenesis common stock valued at USD7.00 per share (with certain non-accredited investors paid approximately USD 20,000 solely in cash) and an assumption of USD 1.9 million in liabilities, estimated to be substantially all of Koligos liabilities. Orgenesis acquired substantially all the assets of Tissue Genesis for an additional consideration of USD 500,000 in closing cash and future royalties. Additional details of the transactions will be available in the Companys Form 8-K, which will be filed with the Securities and Exchange Commission, and will be available atwww.sec.gov.
Pearl Cohen Zedek Latzer Baratz LLP and KPMG advised Orgenesis on the Koligo Transaction. Maxim Group LLC acted as a finder and Nelson Mullins Riley & Scarborough, LLP advised Koligo on the Transaction.
About Orgenesis
Orgenesis is a global biotech company working to unlock the full potential of celland gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCarePlatform is comprised of three enabling components: a pipeline of licensedPOCare Therapeuticsthat are processed and produced in closed, automatedPOCare Technologysystems across a collaborativePOCare Network. Orgenesisidentifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. Learn more about the work Orgenesis is doing atwww.orgenesis.com.
Notice Regarding Forward-Looking Statements
The information in this release is as of October 19, 2020. Orgenesis assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments. This release contains forward looking statements about Orgenesis, Koligo, Koligos technology, and potential development and business opportunities of Koligo and Orgenesis following the closing of the Transaction, each of which involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of the Companys products; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any such regulatory authorities may approved the Companys development products, and, if approved, whether such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of the Companys products; uncertainties regarding the impact of COVID-19 on the Companys business, operations and financial results and competitive developments.
A further description of risks and uncertainties can be found in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available atwww.sec.gov.
The rest is here:
Orgenesis completes acquisition of Koligo Therapeutics and announces additional acquisition of Icellator(R) Technology from Tissue Genesis in related...
- Stem Cell Therapy Los Angeles - Darrow Stem Cell Institute - February 14th, 2021
- Stem Cell Transplants: A Lifesaving Treatment for Cancer ... - February 14th, 2021
- Smart Stem Cells Made From Fat Have the Power to Heal - Freethink - February 14th, 2021
- Are Covid-19 vaccines safe for cancer patients? Here is what cancer experts say - CNN - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Arlo's Army: mum opens up on heartbreaking decision to make 3-year-old sick to save his life - Glasgow Live - February 14th, 2021
- Bone marrow transplant shows signs of curing brave little boy with one in a million condition - Shields Gazette - February 14th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 2nd, 2021
- State-of-the-Art Treatments Garner University Foot and Ankle Institute Multiple Top Doctor Awards - Yahoo Finance - February 2nd, 2021
- Dean Tracy Johnson seeks to diversify the pipeline of future scientists and doctors - UCLA Newsroom - February 2nd, 2021
- Transforming optimism: finding new ways to treat rare cancers - Cancer Research UK - Science Blog - February 2nd, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 2nd, 2021
- Doctor: COVID-19 cases will continue to slowly go down, but were not out of the woods - Yahoo Money - January 23rd, 2021
- Global Precision Medicine Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 - KSU | The... - January 23rd, 2021
- Leading Urologist Doubles Down on CaverStem Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men - PRNewswire - January 22nd, 2021
- Sisters who organised an Ilkley fundraising ball are to be honoured - Wharfedale Observer - January 22nd, 2021
- Medical Doctor: Roes Overlooking of the Consensus of Societal Morality and Science Reverberates to This Day - National Catholic Register - January 22nd, 2021
- DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL)... - January 22nd, 2021
- Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire - January 14th, 2021
- Flow Cytometry Market is Projected to Reach a Value of US$8100 Mn by the End of 2025 - KSU | The Sentinel Newspaper - January 14th, 2021
- Doctors diagnosed a Suffolk teen with a rare condition. Now, his mom is part of the solution - 13newsnow.com WVEC - January 12th, 2021
- Cassville club assists 2 families as they recover from illness - telegraphherald.com - January 12th, 2021
- The 26 billion-dollar startups to watch that are revolutionizing healthcare in 2021 - Business Insider - January 12th, 2021
- Global Precision Medicine Market 2020 Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure... - January 12th, 2021
- More than 250 articles and a book later, the Valley Doctor bids adieu - San Lorenzo Valley Press-Banner - January 12th, 2021
- Groundbreaking Treatment for Severe COVID-19 Using Stem Cells It's Like Smart Bomb Technology in the Lung - SciTechDaily - January 5th, 2021
- New combo therapy offered against refractory T-cell lymphoma - Korea Biomedical Review - January 5th, 2021
- Hair Growth Treatment Secrets Bollywood Will Never Tell You About - Times of India - January 5th, 2021
- Are metabolic hormones the next frontier in cancer treatment? - MedCity News - January 5th, 2021
- Limerick toddler to wait six months for trial cancer treatment after family raises over 400,000 - Extra.ie - January 5th, 2021
- West Lothian mum fighting for her life after back pain turned out to be terminal blood cancer - Edinburgh Live - January 5th, 2021
- MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab - Yahoo Finance UK - January 5th, 2021
- A Wish Come True urges plungers to dump a bucket of ice water on themselves for this year's fundraiser - Fall River Herald News - December 26th, 2020
- Ashley Cain says over 80,000 people registered for stem cell donation in 48 hours after appeal to save baby - The Sun - December 22nd, 2020
- The 11 most mind-blowing, awe-inspiring health discoveries and innovations of 2020 - Business Insider - Business Insider - December 22nd, 2020
- 3-year-old patient successfully treated for rare fatal disease- familial Hemophagocytic lymphohistiocytosis (HLH) at Fortis Hospital Shalimar Bagh -... - December 22nd, 2020
- Startups are racing to reproduce breast milk in the lab - MIT Technology Review - December 22nd, 2020
- Hand weakness: Causes, symptoms, treatment, and seeking help - Medical News Today - December 22nd, 2020
- Gujarat Issues Health Advisory On Fungal Infection With "50% Mortality Rate" - NDTV - December 22nd, 2020
- A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines - STAT - December 22nd, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - Business Wire - December 9th, 2020
- Medical technologies that will disrupt (and improve) healthcare in the 2020s - Universe.byu.edu - December 9th, 2020
- Community Cord Blood Banking saves life of child with aplastic anaemia - The Hindu - November 20th, 2020
- Arya Lloyd: Father launches global search for blood stem cell donor to save his 12-year-old daughter - Sky News - November 20th, 2020
- Blood Cancer: Science Reveal Five Easily Missed Signs of Leukemia - Science Times - November 20th, 2020
- Karnataka:Community cord blood banking emerges as lifesaver - United News of India - November 18th, 2020
- How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment - Curetoday.com - November 16th, 2020
- Election results for California Propositions 14, 18, 23, and 24 - FOX 11 Los Angeles - November 16th, 2020
- Cell Separation Beads Market to Witness Robust Expansion Throughout the Forecast Period 2018-2028 - The Daily Philadelphian - November 16th, 2020
- Fight for the rights of unborn - The Daily Telegram - November 11th, 2020
- Genetic Mechanism Identified in Neonatal Diabetes Could Offer Insights into Other Forms of the Disease - Genetic Engineering & Biotechnology News - November 11th, 2020
- Doctors Debate: Is Intensive or Low-Intensity Chemotherapy Plus BCR-ABL TKI Therapy Best for Treatment of Ph+ ALL? - Targeted Oncology - November 11th, 2020
- Record number of stem cell donors apply after Ex On The Beach star plea - expressandstar.com - November 11th, 2020
- Bisbee: A commitment to health care initiatives The Journal Record - Journal Record - November 11th, 2020
- California election results: Where state propositions stand as of Thursday at 5 p.m. - Desert Sun - November 11th, 2020
- Critically ill Indonesian woman thanks Taiwan for saving life - Taiwan News - November 7th, 2020
- City of Hope Doctors Present New Research on Bone Marrow Transplants, Immunotherapy and Other Blood Cancer Treatments - Business Wire - November 7th, 2020
- Daily Edition for Wednesday, November 4, 2020 - California Healthline - November 7th, 2020
- 'We're truly blood brothers' - Stanford coach David Shaw and his recent fight to save his brother, Eric - ESPN - November 7th, 2020
- 'We're really blood brothers' - Stanford coach David Shaw and his current battle to save lots of his brother, Eric - The Shepherd of the Hills Gazette - November 7th, 2020
- Mark Drought: Are we on the brink of another civil war? - The Advocate - November 7th, 2020
- What to eat when you have the flu, recommended by doctors - Business Insider India - October 30th, 2020
- Fine-Tuning Treatments for COVID-19 - American Council on Science and Health - October 30th, 2020
- Aborted girl fetus kidneys made Trumps CoV meds. As SARS2 is unfettered in America, this needs thought - Feminine-Perspective Magazine (FPMag) - October 30th, 2020
- What to Know in Washington: Provisional Ballots May Play Role - Bloomberg Government - October 30th, 2020
- Unless the country invests in cancer care, the statistics for breast cancer will be bleak: Dr Anthony Pais, .. - ETHealthworld.com - October 23rd, 2020
- Autologous Fat Grafting Market Scope Analysis 2019 to 2029 - The Think Curiouser - October 23rd, 2020
- How Clinique La Prairie Is Keeping Humanity Fashionably Healthy In The Age Of Covid - Forbes - October 23rd, 2020
- The Anthony Nolan and NHS Stem Cell Registry - The Hippocratic Post - October 21st, 2020
- Jeff Bridges is one of the 85,000-plus lymphoma cases expected in the U.S. this year - MarketWatch - October 21st, 2020
- YOUR HEALTH: Saving an unborn baby breaking apart in the womb - WQAD.com - October 21st, 2020
- SA becomes 2nd country to allow 16 and 17-year-olds to donate bone marrow - News24 - October 21st, 2020
- Stem Cell Therapy Market to Witness Steady Expansion During 2025 KYT24 - KYT24 - October 21st, 2020
- Mohammed Hussain Alqahtani shares his insights about the evolution of plastic surgery - LA Progressive - October 21st, 2020
- Manya Saaraswat Makes Top 5 Finish in 2020 Miss World America Competition, Three Other Indian Americans in Top 10 - India West - October 21st, 2020
- Banking wisdom: Teen saving stem cells in hopes of future treatment - LubbockOnline.com - October 15th, 2020
- Mohammed Hussain Alqahtani Discusses the Future of Plastic Surgery - The Jerusalem Post - October 15th, 2020
- The story of how a biotech co. came to the aid of an ill 9-year-old boy - Stockhouse - October 15th, 2020
- Where Amy Coney Barrett Stands on IVF - Glamour - October 15th, 2020